Begin main content

Ibrutinib (Imbruvica) for Leukemia

Brand Name Imbruvica
Generic Name Ibrutinib
Tumour Type Leukemia
Indication In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
Review Status Not Filed
Manufacturer Janssen Canada Inc.
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
Last Updated July 17, 2019